EDITORIAL to note that in the patients included in this meta-analysis, the prevalence of ACS ranged from 30% to 52%, and the time to randomization was within 2 weeks. Their data supports that aspirin can be dropped in the relatively early phase (within less than 2 weeks) after PCI using DESs, and a dual therapy with any type of DOAC and a P2Y12 inhibitor can be used not only in elective PCI patients, but also ACS patients. The mean age was between 68-70 years, and over 90% were white, and thus, there is always a question as to what extent those RCT results can be clinically applied in Japan because only in the RE-DUAL PCI trial, were a small number of Japanese patients (n = 111) enroled. In clinical practice, Japanese AF patients tend to be elderly and have a lower body weight and multiple co-morbidities treated by multiple medications. Furthermore, Asians including Japanese have been known to be at higher risk of bleeding than Westerners. An adjusted-dose (3.75 mg) prasugrel, one of the P2Y12 inhibitors, is used for Japanese patients, and it was not included in those RCTs. Despite those unresolved issues, this meta-analysis and four clinical trials on DOACs used in PCI patients will advance the future guidelines regarding the efficacy of a dual therapy with different types of DOACs in AF patients with CAD and may give cardiologists confidence in dual therapies during the early phase after PCI.
Editorial to the "safety and efficacy of direct oral anticoagulants compared to vitamin K antagonist post percutaneous coronary artery interventions in patients with atrial fibrillation: A systematic revie and meta-analysis"
Atrial fibrillation (AF) and coronary artery disease (CAD) sometimes coexist in clinical practice, and the prevalence of CAD in AF patients and AF in percutaneous coronary artery intervention (PCI) patients has been reported to be around 8%-15% in Japan. Those patients are problematic because bleeding and subsequent complications are substantially increased by a combination antithrombotic therapy with anticoagulants and antiplatelet drugs, that is, an oral anticoagulant plus a P2Y12 inhibitor (double therapy) and triple therapy (an oral anticoagulant plus a dual antiplatelet therapy [DAPT]). That antithrombotic therapy has clinically been up to the physicians' discretion based on careful consideration to balance the ischemic vs. bleeding risks.
Clinical interest in managing antithrombotic therapy in AF patients undergoing PCI has provided several randomized controlled trials (RCTs). First, the WOEST trial 1 (n = 573) tested the clinical benefit of a dual therapy with a vitamin K antagonist (VKA) plus clopidogrel as a counterpart to the triple therapy of a VKA plus a DAPT.
Dual therapy reduced the incidence of major bleeding more than triple therapy, and the incidence of composite cardiovascular events was lower with dual therapy. Furthermore, the PIONEER PCI trial 2 compared the efficacy and safety between dual therapy with rivaroxaban 15 mg plus a P2Y12 inhibitor (n = 709) and triple therapy with a VKA plus DAPT adjusted for 1, 6, or 12 months (n = 706). Similar to the WOEST trial, dual therapy had a lower bleeding risk, but the efficacy endpoint was similar between the dual and triple therapies. A similar tendency was observed in the RE-DUAL PCI trial 3 (n = 2725) to compare a dual therapy with dabigatran over 12 months and a P2Y12 inhibitor and VKA-based triple therapy for 1 to 3 months.
Those trials lead to a significant trend in the Recent European and 
